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ABSTRACT
An astounding feature of the DNA sequences termed CpG motifs is the induction of immune and inflammatory
responses in a senseless manner. CpG motifs exist abundantly in microbes and evoke innate immunity that
constitutes the first line of defense against microbial infections in vertebrates. CpG motifs that essentially work
in an antigen-nonspecific fashion, however, turn into novel immunomodulators that can manipulate acquired
immunity in an antigen-specific manner if oligodeoxynucleotides containing CpG motifs (CpG ODNs) are di-
rectly conjugated to the antigen. CpG ODNs with potent polyclonal Th1-inducing ability show promise for appli-
cation in immunotherapy whereby neutralization of dominant allergy-prone Th2 cells is achieved by inducing
allergen-specific Th1 cells. The underlying mechanisms include an unexpected enhancement of dendritic cell
function as a linker between innate and acquired immunity. In the foreseeable future the mainstream therapeu-
tic role of corticosteroids in anti-inflammatory therapy for allergic diseases could possibly be replaced by immu-
notherapy using CpG ODN-conjugated antigens．
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INTRODUCTION
In recent years the incidence of various allergic dis-
eases, including allergic rhinitis, bronchial asthma,
and atopic dermatitis, has been increasing through-
out the world. Although manifestations vary accord-
ing to disease, the fundamental pathophysiologic ab-
normalities underlying these diseases are now con-
sidered to be related to the overreaction of Th2 cells
to allergens. Novel immunotherapies to treat allergic
diseases by inhibiting the causal Th2 cells are there-
fore anticipated.
REGULATION OF IMMUNE RESPONSES BY
T CELLS
Apart from pathogenic microbes, the majority of aller-
gens are innocuous in nature. Allergens do not multi-
ply inside the body. They do not directly destroy tis-
sues. The immune system could ignore them with
impunity. For some unknown reasons, however, the
immune surveillance system evokes disadvantageous
responses to the allergens, resulting in the onset and
perpetuation of allergic diseases. Among a miriade of
cells involved in allergic inflammation, Th2 cells are
considered the prime lymphocyte subset that dictates
a series of allergic reactions.
The immune system appears to be tightly and
smartly regulated by various regulatory mechanisms.
Among others, T cells have been attracting much at-
tention especially with respect to antigen specificity
and major histocompatibility complex ( MHC ) -
restriction specificity at the induction and effector
phases. T cells with regulatory functions were for-
merly called suppressor T cells.1 After a lull in exten-
sive investigations on suppressor T cells there has
been a resurgence in research with accompanying
new terminology, whereby regulatory T cells have re-
placed the old term for suppressor T cells.2-5 Regula-
tory and suppressor T cells manifest their principle
activities by inhibiting other T cell subsets . Recent
advances have enabled us to identify the effector
regulatory molecules, such as TGF-β, IL-10 or CTLA-
4.2,3,6,7
Some effector T cells can also exert inhibitory func-
tions on other T cells. Typical examples are Th1 and
Th2 cells. Th1 and Th2 cells were defined on the ba-
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sis of the specific cytokines they secrete.8 A particu-
larly intriguing phenomenon is that Th1 and Th2
cells with the same antigen specificity mutually in-
hibit each other’s effector functions.9,10 These origi-
nal findings have contributed to furthering the under-
standing of the basic abnormalities in various dis-
eases and are leading the way toward the develop-
ment of future therapies . Allergic diseases are a
prime candidate for immunotherapy, due to the na-
ture of distal upstream antigen-specific Th 2 cells
which dictate most allergic manifestations．
CPG MOTIFS AND ACQUIRED IMMUNITY
The function of DNA had long been regarded as lim-
ited to the transmission of the genetic information.
This dogma was challenged by the astounding find-
ings of Tokunaga and his group.11 They reported that
DNA itself directly activates NK cells in a senseless
manner.12,13 These functions were localized specifi-
cally to particular sequences of DNA,14 now called
CpG motifs (Fig. 1).
CpG motifs are frequently found in bacteria , but
rarely in vertebrates. Vertebrates recognize CpG mo-
tifs as non-self. During the long evolutionary process,
vertebrates have somehow acquired the ability to ex-
ploit these differences for protection against patho-
genic infections. The presence of CpG motifs inside
the body is interpreted as an invasion by microorgan-
isms, and as a result defensive immune and inflam-
matory responses are evoked．
The recognition of microbes is often mediated by
receptors that have evolved to bind selectively to
structures expressed solely in microbes but not in
self-tissues.15 So far, 10 different kinds of receptors,
collectively called toll-like receptors (TLR), have been
discovered. One of the TLRs, TLR9, specifically rec-
ognizes CpG motifs,16-18 and the colocalization of CpG
motifs with TLR9 is the initial step that ultimately
leads to the activation of the acquired immune sys-
tem, namely T and B cells.19,20
One of the outstanding characteristics of the ac-
quired immune system is the antigen-specificity at
the induction and effector phases. The most efficient
immune responses are attained when they are
evoked in an antigen-specific manner, as is the case
with preventive vaccines against microbial infections.
However, the effects of CpG motifs on acquired im-
munity are polyclonal in nature since CpG motifs do
not possess inherent antigenic information . Treat-
ment with CpG motifs may only stir the sophisticated
immune regulation．
Since synthetic oligodeoxynucleotides containing
CpG motifs (CpG ODNs) mimic the activity of bacte-
rial DNA, CpG ODNs have been used to explore the
nature of CpG motifs. In the following discussion, we
shall mainly focus on experimental applications of
CpG ODNs for the treatment of bronchial asthma in
murine models.
CPG ODNS AS ANTIGEN-NONSPECIFIC IN-
HIBITORS OF ALLERGIC INFLAMMATION
Early attempts to reduce allergic airway inflammation
were made by administering CpG ODNs without an
accompanying antigen. Intraperitoneal or intranasal
administration of CpG ODNs was reported to inhibit
airway eosinophilia and improve airway hyperrespon-
siveness. These anti-allergic effects were concomitant
with decreases in IL-5 secretion from CD4+ spleen
cells or decreases in IL-4 levels in bronchoalveolar
lavage.21,22 Increased levels of Th1 cytokines, such as
IFN-γ and IL-12, were also noted.21,22
The mechanisms underlying these observations
have remained unknown. CpG ODNs induced the ex-
pression of costimulatory molecules23,24 and IL-1225,26
in dendritic cells (DCs), which are required for the
induction of Th1 cells. When these changes were in-
duced independently of the attendant antigen, CpG
ODNs would plausibly drive immune responses to
skew toward a Th1-dominant phenotype in an
antigen-nonspecific fashion, which would in turn in-
hibit allergen-specific Th2 cells in a bystander man-
ner. In another scenario, CpG ODN-induced Th1 cy-
tokines, including IFN-γ and IL-12, may inhibit Th2-
mediated inflammation without direct participation of
CpG ODN-induced Th1 cells．
Recently , CpG ODN treatment was found to in-
crease the levels of bronchoalveolar lavage TGF-β in
a murine asthma model.27 The authors suggested the
possible induction of regulatory T cells by CpG
ODNs, although no evidence for the production of
TGF-β from T cells was demonstrated．
Regardless of the mechanisms, manipulations by
CpG ODNs alone required larger doses of CpG
ODNs than that by CpG ODNs with concomitant anti-
gen to attain comparable therapeutic effects . Treat-
ment with high doses of CpG ODNs could eventually
highlight the intrinsic adverse effects of CpG motifs,
such as an increase in serum TNF-α levels or mortal-
ity.28-30 In light of the pathogenic roles of Th1 cells in
various types of autoimmunity,31 the effects of CpG
motifs on the activation of autoreactive Th1 cells and
autoimmunity are also unpredictable and controver-
sial.32-35
Another report showed that treatment with CpG
ODNs plus corticosteroids was synergistically more
effective than monotherapy with either agent alone.36
Since neither CpG ODNs nor corticosteroids manipu-
late the immune response in an antigen-specific man-
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Fig. 2　Comparison of the conjugate with the mixture of 
CpG ODNs and OVA. OVA-primed BALB/c mice were pre-
treated intratrachealy with graded doses of the conjugate 
(■) or a mixture (□) of CpG ODNs and OVA before OVA 
chalenge. The airway eosinophilias were expressed as a 
percentage relative to the control response. The covalent 
conjugate was calculated to be 100-fold more potent in the 

























0.01 0.1 101 Fig. 3　Three conditions required for the induction of 
antigen-specific Th1 cels. The conditions are as folows: ①
presentation of antigenic peptides in the context of MHC 
class I molecule by antigen presenting cels, particularly 
dendritic cels② maturation and ful activation of dendritic 
cels for the expression of costimulatory molecules, includ-
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ner, treatment with the CpG ODNs would represent
nothing more than an anti-inflammatory therapy, the
same effect as corticosteroids．
INHIBITION OF ALLERGIC INFLAMMATION
BY CPG ODNS IN AN ANTIGEN-SPECIFIC
MANNER
It is well known that Th1 and Th2 cells work in a mu-
tually inhibitory manner when both cells recognize
the same antige . 10 CpG motifs have diverse proin-
flammatory and immuno-potentiating actions, includ-
ing Th1 induction, although these actions are inde-
pendent of specific antigens．
In order to augment the potentiation of adjuvant
use of CpG motifs in the antigen-specific Th1 re-
sponses, CpG ODNs are often coadministered with
the antigen . Actually , this idea has demonstrated
positive results. Inhibition of airway allergic inflam-
mation was achieved with smaller doses of CpG
ODNs when administered together with antigen than
when given alone.37,38 The anti-inflammatory activity
was accompanied by the improvement of airway hy-
perresponsiveness and the inhibition of Th2 cytoki-
nes.37,38 The absence of IFN-γ nullified the CpG OD-
Ns’ effects , suggesting the possibility for Th1 cell
contribution in the inhibition of Th2 cells.37
Established airway eosinophilia was also improved
by treatment with CpG ODNs and antigen.39,40 In par-
allel, an improvement of airway hyperresponsiveness
and a decrease in Th2 cytokines in the bronchoalveo-
lar lavage was also observed. An interesting finding
was an increase in IL-10 production and decreases in
IL-5 and IFN-γ production from splenocytes treated
with antigen and CpG ODNs.40 These findings might
imply that CpG ODN immunotherapy induces regula-
tory T cells other than Th1 cells.
DIRECT CONJUGATION OF CPG ODNS TO
ANTIGEN
Since coadministration of antigen and CpG ODNs ex-
erted potent anti-allergic effects , direct linkage be-
tween antigens and CpG ODNs was introduced to as-
sure intimate contact between the two. As a result,
the conjugated form of CpG ODNs plus antigen was
100-fold more efficient in regulating airway eosino-
philia than the unconjugated mixture (Fig. 2). The in-
hibition of airway eosinophilia by the conjugate was
antigen-specific, and occurred in parallel with the un-
responsiveness of the antigen-specific Th2 cells in the
regional lymph nodes.41 Airway hyperresponsiveness
was also improved.41,42
In accord with these in vivo observations, the CpG
ODN-antigen conjugate was 100-fold more effective
than the unconjugated mixture for inducing in vitro
Th1 differentiation in an IL-12-dependent manner.41
Thus, the antigen-specific Th1 cells are induced effi-
ciently by the conjugate of CpG ODNs and antigen,
and in turn inhibited the Th2 cells dictating allergic
inflammation. The CpG motifs were essential as evi-
denced by a failure of a conjugate between antigen
and ODNs containing no CpG motifs to induce Th1
cells. Marshall et al. reported that human peripheral
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Fig. 4　Advantages of conjugates for Th1 induction. Conjugates between antigens and CpG ODNs first bind to 
DNA receptors expressed on the surfaces of APCs, and are then incorporated into endosomes by receptor-medi-
ated endocytosis (a). The amounts of antigens incorporated by APCs are greater when the antigens are captured 
by receptor-mediated endocytosis than compared to ordinary fluid phase endocytosis. The antigens are digested 
and transfered to the cel surface for the presentation to T cels. On the other hand, endocytosed CpG ODNs 
colocalize with TLR9 in the late endosomes (c), which trigger activation signals ultimately leading to the expres-
sion of costimulatory molecules and the IL-12 secretion. Thus, APCs that fulfil the three conditions shown in Fig-
ure 3 induce the diferentiation and activation of Th1 cels. ODNs lacking CpG motifs, which can bind to surface 
DNA receptors and are endocytosed, however, fail to transmit the activation signal due to the inability to colocal-














Fig. 5　Absence of need for TLR9 in CpG ODN-mediated Ag uptake by Ia+ cels
APCs from TLR9-deficient (TLR9 KO) or wild type (WT) mice were incubated with 
R-phycoerythrin (PE) conjugated with CpG ODNs overnight, and examined for the 
expression for PE and CD86. The numbers in figures indicate the percentage of 
cels in each quadrant. CpG ODN-linked antigens were taken up by APCs regard-
less of the expression of TLR9, whereas TLR9 was essential for the activation of 
the APCs as demonstrated by the increased proportion of CD86+ APCs.
WT TLR-9 KO

















20 Allergology International Vol 54, No1, 2005 www.js-allergol.gr.jp
Sano K et al.
blood mononuclear cells from patients with ragweed
allergy shifted from a Th2 to Th1 cytokine expression
pattern when cultured in the presence of the antigen-
linked CpG ODNs.43
Another beneficial aspect of the conjugate is the re-
duction of the allergenicity of antigens. Tighe et al.
reported that antigen conjugated with CpG ODNs
had a diminished ability to react with antigen-specific
IgE as evidenced by reduced histamine release from
human basophils.44 Horner et al. demonstrated that
increases in the ODN conjugation to antigen ratio re-
sulted in parallel increases in immunogenicity and de-
creases in allergenicity . 45 These findings , together
with a previous report that CpG ODNs directly inhib-
ited IgE synthesis from B cells through the induction
of T-bet,46 highlight the effectivity of CpG ODNs in
IgE regulation and offer a possible clinical application
for safer immunotherapy.
An extended period of efficacy is another advanta-
geous aspect of conjugates . Horner et al. reported
that the conjugate-induced Th1-biased immune re-
sponses were maintained for at least 1 year , 47
whereas allergen-independent immunomodulation by
CpG ODNs alone was shown to persist for a much
shorter period of time.48 Differences in the durability
might simply reflect differences in the underlying
mechanisms involved ; conjugates and CpG ODNs
work on acquired and innate immunity, respectively.
In addition to applications for allergies, CpG ODN-
conjugated antigen was also shown to be beneficial in
the treatment of malignant tumors. Melanoma cells
were eradicated by the activation of CD8+ CTLs in-




The mechanism for the enhancement of Antigen-
specific Th1 responses by the conjugate is of signifi-
cant interest. Based on the fact that the conjugated
forms of antigen and CpG ODNs are in close proxim-
ity to each other, initially it seemed conceivable that
simultaneous engulfment of both antigen and CpG
ODNs was the main reason for the enhanced induc-
tion of antigen-specific Th1 cells.41,49
This notion appeared sensible in light of a consid-
eration of the requisites for Th1 induction. Three con-
ditions need to be fulfilled for the efficient induction
of antigen-specific Th1 cells (Fig. 3);  presentation
of antigenic peptides in the context of MHC class II
molecule by antigen presenting cells , particularly
dendritic cells maturation and complete activation
of dendritic cells in the expression of costimulatory
molecules, including CD80 and CD86 secretion of
IL-12 from dendritic cells. The first condition derives
from the phagocytosedendocytosed antigen, and the
second and third conditions are provided by CpG
ODNs. Thus, the incorporation of the conjugate by
antigen-presenting cells (APCs) appears to simultane-
ously fulfill the three conditions listed above. How-
ever, this was not the end of the story．
CpG ODNs in the conjugated form had unexpected
advantages in facilitating antigen uptake by APCs. Im-
mature DCs are considered to be well equipped with
devices for antigen capture,50 although the actual an-
tigen capture is primarily mediated by fluid-phase en-
docytosis.51 DCs randomly take up antigens that hap-
pen to be in the adjacent neighborhood. In the conju-
gated form of the CpG ODNs and antigen, however,
CpG ODNs work like “glue” to facilitate the adhesion
of the conjugate to the cell surfaces of APCs ; CpG
ODNs bind to cell surface receptors for DNA, which
is followed by an increase in antigen uptake by
APCs.52 A quantitative study revealed that antigen
uptake mediated by DNA receptor-mediated endocy-
tosis was 100 times more efficient than that through
fluid-phase endocytosis . Thus , CpG ODNs conju-
gated to antigen exhibit joint properties as promoters
of antigen uptake and DC activators, thereby potenti-
ating the ability of DCs to generate Th1 cells (Fig. 4).
The colonization of CpG ODNs with TLR9 in the
mature and acidified endosomes is an initial and es-
sential step that triggers intracellular signals.16-18,53,54
CpG ODNs, acting as glue, first bind to cell surface
receptors for DNA, but not to TLR9, because TLR9 is
not expressed on the cell surface . Actually , CpG
ODN-conjugated antigens were incorporated into
APCs prepared from TLR9 KO mice to the same ex-
tent as those from wild mice (Fig. 5). The CpG ODN-
conjugated antigen, however , failed to induce Th1
cells due to the lack of the costimulatory molecule ex-
pression and the IL-12 secretion in APCs prepared
from TLR9 KO mice.55
Exogenously administered CpG ODNs first bind to
the cell surface receptors specific for DNA, and enter
cells through receptor-mediated endocytosis55 before
colonization with TLR9 in the endosomallysosomal
compartment . 56 When antigen is conjugated to
ODNs, regardless of the presence or absence of CpG
motifs in the ODN sequences, ODNs bind to DNA re-
ceptors on the cell surfaces to a comparable ex-
tent.55,57 After receptor-mediated endocytosis, ODNs
with CpG motifs colocalize with TLR9 and trigger sig-
nals, whereas those without CpG motifs fail to do so
(Fig. 4). These differences ultimately lead to the pref-
erential induction of Th1 or Th2 cells by ODNs with
or without CpG motifs, respectively.55
FUTURE PROSPECTS
Human clinical trials for ragweed allergic rhinitis us-
ing CpG ODNs conjugated to the principal allergenic
moiety of ragweed (Amb a 1) are currently in pro-
gress in the United States. Six injections of the conju-
gates over 6 weeks were reported to improve symp-
toms without any adverse effects . 58,59 These and
other studies show great promise for future break-
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throughs in immunotherapy on the horizon.
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